001433019 000__ 04501cam\a2200577\a\4500
001433019 001__ 1433019
001433019 003__ OCoLC
001433019 005__ 20230309003545.0
001433019 006__ m\\\\\o\\d\\\\\\\\
001433019 007__ cr\un\nnnunnun
001433019 008__ 201220s2021\\\\sz\\\\\\o\\\\\000\0\eng\d
001433019 019__ $$a1228043705$$a1228843717$$a1236894838$$a1237461639$$a1238201247$$a1241066754$$a1246359547
001433019 020__ $$a9783030573690$$q(electronic bk.)
001433019 020__ $$a3030573699$$q(electronic bk.)
001433019 020__ $$z3030573680
001433019 020__ $$z9783030573683
001433019 0247_ $$a10.1007/978-3-030-57369-0$$2doi
001433019 035__ $$aSP(OCoLC)1227449696
001433019 040__ $$aYDX$$beng$$epn$$cYDX$$dGW5XE$$dUPM$$dBDX$$dOCLCF$$dEBLCP$$dOCLCO$$dDCT$$dOCL$$dOCLCO$$dOCLCQ$$dOCLCO$$dCOM$$dN$T$$dOCLCQ$$dCASUM
001433019 049__ $$aISEA
001433019 050_4 $$aRM666.C266
001433019 08204 $$a615.7/827$$223
001433019 24500 $$aCannabinoids and neuro-psychiatric disorders /$$cEric Murillo-Rodriguez, S.R. Pandi-Perumal, Jaime M. Monti, editors.
001433019 260__ $$aCham, Switzerland :$$bSpringer,$$c2021.
001433019 300__ $$a1 online resource
001433019 336__ $$atext$$btxt$$2rdacontent
001433019 337__ $$acomputer$$bc$$2rdamedia
001433019 338__ $$aonline resource$$bcr$$2rdacarrier
001433019 347__ $$bPDF
001433019 347__ $$atext file
001433019 4901_ $$aAdvances in Experimental Medicine and Biology,$$x0065-2598 ;$$v1264
001433019 5058_ $$aChapter 2: Neuromolecular Mechanisms of Cannabis Action -- 2.1 Introduction and Scope of this Chapter -- 2.1.1 Neuromolecular Targets of THC: The Cannabinoid Receptors -- 2.1.1.1 CB1 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology -- 2.1.1.2 CB2 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology -- 2.1.2 Neuromolecular Targets of THC: Beyond the Cannabinoid Receptors -- 2.1.3 Neuromolecular Targets of CBD -- 2.1.4 Neuromolecular Targets of Other Cannabinoids -- 2.1.4.1 Delta9-Tetrahydrocannabidivarin
001433019 5058_ $$a2.1.4.2 Cannabinol -- 2.1.4.3 Delta9-Tetrahydrocannabinolic Acid -- 2.1.4.4 Cannabidivarin -- 2.1.4.5 Cannabidiolic Acid -- 2.1.4.6 Cannabigerol -- 2.1.4.7 Cannabichromene -- 2.1.5 Concluding Remarks -- References -- Chapter 3: Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review -- 3.1 Introduction -- 3.2 Neuromolecular mechanisms of action of the main phytocannabinoids -- 3.2.1 THC -- 3.2.2 CBD -- 3.2.3 Delta-9-THCV -- 3.2.4 Delta-9-THCA -- 3.2.5 Delta-8-THC -- 3.2.6 CBDV -- 3.2.7 CBN -- 3.2.8 CBG -- 3.2.9 CBC -- 3.2.10 CBDA
001433019 5058_ $$a3.3 Neurochemical and behavioral effects of THC and CBD: Human studies -- 3.3.1 THC -- 3.3.2 CBD -- 3.4 Approved indications of cannabis-based products, THC and CBD -- 3.4.1 Cannabis-based products -- 3.4.2 THC -- 3.4.2.1 Nausea and vomiting due to chemotherapy -- 3.4.2.2 Appetite and decreasing weight loss associated with HIV/AIDS -- 3.4.2.3 Multiple sclerosis symptoms (spasticity and chronic pain) -- 3.4.2.4 Chronic pain (neuropathic and cancer pain) -- 3.4.3 CBD -- 3.4.3.1 Antiepileptic -- 3.4.3.2 Therapeutic potentials of CBD with moderate/modest evidence from RCTs
001433019 5058_ $$a3.5 Adverse effects of THC and CBD -- 3.5.1 Cannabis-based products and THC -- 3.5.2 CBD -- 3.6 Conclusions -- References -- Chapter 4: Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models -- 4.1 Introduction -- 4.1.1 Cannabinoid Classifications -- 4.2 Endocannabinoids -- 4.3 Phytocannabinoids -- 4.4 Synthetic Cannabinoids -- 4.5 Cannabinoids in Neuromodulation -- 4.5.1 Cannabinoids in Epilepsy -- 4.5.2 Cannabinoids in Alzheimerś Disease -- 4.5.3 Cannabinoids in Parkinsonś Disease -- 4.6 Cannabinoids in Cancer -- 4.7 Cannabinoids in Metabolic Disorders
001433019 506__ $$aAccess limited to authorized users.
001433019 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed February 18, 2021).
001433019 650_0 $$aCannabinoids.
001433019 650_6 $$aCannabinoïdes.
001433019 655_0 $$aElectronic books.
001433019 7001_ $$aMurillo-Rodríguez, Eric,$$eeditor.
001433019 7001_ $$aPandi-Perumal, S. R.,$$eeditor.
001433019 7001_ $$aMonti, Jaime M.,$$eeditor.
001433019 77608 $$iPrint version:$$tCannabinoids and neuro-psychiatric disorders.$$dCham, Switzerland : Springer, 2021$$z3030573680$$z9783030573683$$w(OCoLC)1176328270
001433019 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1264.$$x0065-2598
001433019 852__ $$bebk
001433019 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-57369-0$$zOnline Access$$91397441.1
001433019 909CO $$ooai:library.usi.edu:1433019$$pGLOBAL_SET
001433019 980__ $$aBIB
001433019 980__ $$aEBOOK
001433019 982__ $$aEbook
001433019 983__ $$aOnline
001433019 994__ $$a92$$bISE